Kairos Pharma, Ltd. fell 10.3% on Monday, November 16, 2026, on 12,719 shares. No headline about KAPA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Kairos Pharma, Ltd. (KAPA:NYSEMKT) closed at $0.407 on November 16, 2026, down 10.30% on the day. It is trading at its 52-week low of $0.407. Over the past year, it lost 92.2%. Kairos Pharma, Ltd. is part of the Health Care sector.
In 252 trading sessions since November 14, 2025, KAPA closed higher on 103 days (41%). Its best day was August 6, 2026 (+18.18%) and its worst was October 6, 2026 (-25.81%). The stock moved 10% or more in a single session 19 times. It opened at least 5% above the previous day's high 2 times.
Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviros advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies.
Find more stocks like KAPA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.